Food and beverage companies are continually in need of developing their intellectual property strategies and defending their intellectual property rights.
We work closely with our clients to identify and protect the integrity of their brands to ensure that they distinguish themselves from their competitors. Our food and beverage lawyers also help clients with regulatory matters.
We have handled an array of matters ranging from due diligence to business transactions. Our lawyers also offer a full-range of patent services and obtain patent protection for and manage an establishment of food and beverage patent portfolios in the United States, Europe, Asia, and Australia to achieve clients’ business objectives.
We are skilled in every aspect of advertising and intellectual property within the food industry, including:
Branding, advertising review, and compliance
False advertising litigation
Procurement and management
Litigation regarding patents, trademarks, trade secrets, and copyrights
Food, Drugs, Medical Devices and Cosmetics (FDA)
Due diligence, acquisition, and licensing
Our lawyers have decades of FDA experience. We effectively address the issues and problems that arise for growers, manufacturers, associations, cooperatives and technology providers. Our lawyers also provide crisis management in recall situations, as well as counsel on ingredient, labeling, and advertising matters. Additionally, we provide regulatory strategies for conventional food, functional food, dietary supplements, and medical food. Further, our lawyer’s help clients comply with dietary supplement GMPs, provide representation in enforcement proceedings, and provide a comprehensive range of other services for the food sector.
On 23 December 2020, Judge Catherine Blake of the U.S. District Court for the District of Maryland granted the Pharmaceutical Research and Manufacturers of America (PhRMA) a 14-day nationwide temporary restraining order, preventing the Centers for Medicare and Medicaid Services (CMS) from implementing and enforcing its Most Favored Nation (MFN) interim final rule (MFN Rule) scheduled to take effect on 1 January 2021.
Following earlier announcements as to the efficacy of vaccine trials by pharmaceutical companies Pfizer, Inc. (Pfizer) and Moderna, Inc. on November 20, 2020, Pfizer and BioNTech submitted applications for emergency use authorization to the U.S. Food and Drug Administration (FDA) for their COVID-19 vaccinations.
This alert provides a brief overview of the final rules and the potential policy tools available to the Biden administration should it seek to revisit them.
We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.
